News Conference News AHA 2024 ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery Yael L. Maxwell November 17, 2024
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Conference News AHA 2021 GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients Todd Neale November 14, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2020 Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib Todd Neale November 14, 2020
News Conference News AHA 2018 Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF Todd Neale November 11, 2018
News Conference News AHA 2017 ‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry Todd Neale November 22, 2017
News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
News Conference News AHA 2017 Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma Todd Neale November 15, 2017
News Conference News AHA 2017 Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation Michael O'Riordan November 13, 2017
Presentation AHA 2017 Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial Presenter: Akihiko Nogami November 13, 2017
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News AHA 2015 Is Watchman Cost-effective? That Depends Where You Look Todd Neale November 07, 2015
News Conference News AHA 2012 Evidence Continues to Support Dabigatran Treatment in A-fib November 06, 2012